Mark J. Levis, MD, PhD | Authors


Gilteritinib Monotherapy Shows Potential for Treatment of Relapsed/Refractory FLT3+ AML

August 08, 2019

Patients with relapsed or refractory acute myeloid leukemia typically have low response rates to chemotherapy. However, some subsets of patients, particularly those with targetable mutations, may have long-term survival when given a novel FLT3 inhibitor like gilteritinib, as seen in the ADMIRAL trial, says Mark J. Levis, MD, PhD.

The Background and Future of Quizartinib for AML

November 12, 2013

Mark J. Levis, MD, PhD, Johns Hopkins University, discusses the background and future of quizartinib for FLT3-ITD acute myeloid leukemia at the 2013 Chemotherapy Foundation Symposium, which took place from November 6-8.